JNJ's 64-year dividend raise streak pairs with 53% one-year price gains, while PEP yields 4% after its record-high 54th consecutive annual increase. McDonald's dropped 10% YTD yet beat Q2 EPS estimates and counts 220 million loyalty users generating over $40 billion in systemwide sales. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut.
Grab the names FREE today. While the market chases AI multiples and momentum trades, a quiet cohort of blue-chip dividend compounders continues doing what it has done for decades: raise the payout, return capital, and reward patience. The five names below are all Dividend Kings or Aristocrats with streaks measured in generations, not quarters.
Dividend safety leads the thesis here, with each pick backed by cash flow, brand moats, and a fresh raise this year. Prices and yields referenced below reflect data as of August 14, 2026. Here is the case for each.
Johnson & Johnson (NYSE:JNJ) is the anchor of any dependable dividend book. The board raised the quarterly dividend 3.1% to $1.34 per share this spring, marking 64 consecutive years of increases. The next payment lands September 8, 2026, following an August 25 ex-date.
The bull case tightened in Q1 2026, when revenue hit $24.06B (+9.9% YoY) with adjusted EPS of $2.70, beating expectations. Oncology is doing the heavy lifting: DARZALEX at $3.96B (+22.5%), TREMFYA up 68.3%, and CARVYKTI up 62.1%. Shares have delivered 27.2% YTD and 52.73% over one year, a rare growth-plus-yield combination for a stock with a beta of 0.231.
Risk: STELARA biosimilar erosion (-59.7%) is a meaningful revenue headwind, and litigation charges of $330M in Q1 remind investors that legal overhang has not gone away. Procter & Gamble (NYSE:PG) owns the longest income record on this list: 70 consecutive years of dividend increases and 136 consecutive years of payments. The current quarterly dividend of $1.0885 supports an annualized forward payout of $4.354, yielding roughly 2.95% at recent prices.
Extract — continue reading at the source.
